Moderna Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Moderna key operating metrics including Program Expenses (Systemic Intracellular Therapeutics), environmental, and social and governance score (ESG).

Program Expenses (Systemic Intracellular Therapeutics)

$4M

20.0%

Q1, 2022

Program Expenses (Cancer Vaccines)

$3M

82.4%

Q1, 2022

Patent Applications

430

28.3%

FY, 2021

Operating Metrics

Metrics	FY, 2019	FY, 2020	FY, 2021
Program Expenses (Systemic Intracellular Therapeutics)	$33.4M	$21.0M	$26.0M
Program Expenses (Cancer Vaccines)	$44.0M	$29.4M	$47.0M
Patent Applications	560	600	430
Patents (US)	115	145	170
Patents (Foreign)	100	125	110
Active Clinical Studies	12	13	23
Clinical Programs	23	24	40
Patents Issued	210	270
Program Expenses (Prophylactic Vaccines)	$47.7M	$707.2M	$1.1B
Program Expenses (Intratumoral Immuno-Oncology)	$17.6M	$8.8M	$20.0M
Program Expenses (Localized Regenerative Therapeutics)	$3.3M	$4.0K
Program Expenses (Systemic Secreted and Cell Surface Therapeutics)	$11.2M	$1.5M	$3.0M
Vaccines Sold, doses			807M

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub